– Dante Genomics receives a grant for a whole genome sequencing project aimed at measuring the utility of pharmacogenomics in a real clinical setting
– A coveted innovation grant from the Italian government will measure the impact of whole genome sequencing and pharmacogenomics from a targeted population of cancer patients —
NEW YORK, April 27, 2023/PRNewswire/ — Dante Genomics, a world leader in genomics and precision medicine, today announced that it has received a coveted innovation grant from the Italian government to measure the impact of whole genome sequencing and pharmacogenomics in patients with high-grade serous ovarian cancer (HSOC). The immediate goal is to measure the clinical utility of whole genome sequencing for this well-defined population of cancer patients in a clinical setting and the benefits to the entire healthcare system.
“Our common long-term goal is to create a pathway for the use of whole genome sequencing in real clinical settings within a national healthcare system,” said Andrea Riposati, Co-Founder and CEO of Dante Genomics. “We started in Italy, a founding member of the European Union and a G7 country with a population of 60 million, and in a healthcare system eager to innovate.”
The grant will fund a pilot study with patients in which Dante will provide genomic sequencing, interpretation, and reporting to demonstrate the validity of whole genome sequencing to assist clinicians and their patients in all stages of treatment, from diagnosis to triage of treatment and consultation with specialists, which in the long run will result in better health outcomes.
“Whole genome sequencing for cancer patients can make all the difference in determining the best treatment plan in a timely manner. Starting with whole genome sequencing, we can offer available pharmacogenomic reports within minutes, which determine the best drugs on the market and any resistance to existing therapies. This project with the Italian government will increase access to personalized medicine options for people with high-grade serous ovarian cancer,” explained Mattia Capulli, PhD, Co-Founder and Chief Scientific Officer of Dante Genomics and Associate Professor of Human Embryology and Histology at the University of L’Aquila in Italy.
The 36-month project aims to establish a proof-of-concept demonstrating how deep integration of genomics and bioinformatics in the treatment of cancer patients dramatically improves cancer treatment outcomes.
About Dante Genomics
Dante Genomics is a global genomics information company creating and commercializing a new class of transformative applications for health and longevity based on whole genome sequencing and software. The company uses its platform to deliver better patient outcomes, prevention, improved diagnostics, and personalized medicine. The company’s assets include one of the largest private consent-based genomic databases for research, proprietary software designed to unleash the power of genomic data at scale, and proprietary processes that enable an industrial approach to genomic sequencing.
Contact:Laura D’AngeloVice President of Investor Relationsir@dantelabs.com 39 0862 191 0671 www.dantegenomics.com
Logo – https://mma.prnewswire.com/media/2035834/4008003/Dante_Genomics_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/dante-genomics-recibe-una-subvencion-para-un-proyecto-de-secuenciacion-del-genoma-completo-301809999.html
